COMMUNIQUÉS West-GlobeNewswire

The Ensign Group Schedules Year-End 2023 Earnings Call for Friday, February 2, 2024
30/01/2024
SAN JUAN CAPISTRANO, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
RevoluGen Demonstrates Superior Automated Magnetic Bead-Based HMW-DNA Extraction with its Fire Monkey Chemistry Under Collaboration with LGC Biosearch Technologies
30/01/2024
HADFIELD, United Kingdom, Jan. 30, 2024 (GLOBE NEWSWIRE) -- UK genomics company, RevoluGen Ltd., has demonstrated a new protocol for automated bead-based high molecular weight HMW-DNA extraction with its proprietary [...]
High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies
30/01/2024
Press Release High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies. The three partners are [...]
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)
30/01/2024
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0. [...]
Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)
30/01/2024
Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV) Les deux groupes de traitement associant le [...]
INTERIM REPORT FOR Q1 2023/24
30/01/2024
In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT [...]
PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy
30/01/2024
Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune diseases, announced that Prof. Piotr [...]
BioSenic patent granted in Canada for broader protection of ATO therapeutic platform
30/01/2024
PRESS RELEASE – INSIDE INFORMATION BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through [...]
Le brevet de BioSenic est accordé au Canada pour une protection plus large de sa plate-forme thérapeutique ATO
30/01/2024
COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE Le brevet de BioSenic est accordé au Canada pour une protection plus large de sa plate-forme thérapeutique ATO Le brevet sur la composition de la matière couvre l' [...]
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
30/01/2024
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE ® is the first oral targeted therapy approved in Hong Kong for [...]
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
30/01/2024
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious [...]
Among the ongoing attacks on Ukraine, religious leaders aim to unite the Ukrainian religious diaspora and foster collaboration between Ukraine and the U.S. through Ukrainian Week 2024
30/01/2024
Ukrainian soldiers, returned children from Russia and Ukrainian delegates and parliament members set to attend Ukrainian Week 2024 WASHINGTON, D.C. and KYIV, Ukraine, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Today, prominent [...]
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
29/01/2024
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosis Combination of SCY-247 and Liposomal Amphotericin B [...]
Castellum Announces Closing of $2.7 Million Registered Direct Offering
29/01/2024
BETHESDA, Md., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government today announced [...]
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
29/01/2024
The UK MHRA approval follows approvals by the U.S. FDA and the European Commission Cidara is entitled to receive a milestone payment of approximately $2.8 million from Mundipharma SAN DIEGO, Jan. 29, 2024 (GLOBE [...]
Dentsply Sirona to Host Fourth Quarter and Full Year 2023 Conference Call on February 29th
29/01/2024
CHARLOTTE, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast [...]
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
29/01/2024
PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand [...]
Nanobiotix annonce l’atteinte des conditions pour un paiement d'étape de développement de 20 M$ lié à l'étude mondiale de phase 3 en cours sur le cancer de la tête et du cou
29/01/2024
PARIS et CAMBRIDGE, Mass., 29 janv. 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Immunocore Announces Proposed Convertible Senior Notes Offering
29/01/2024
Immunocore Announces Proposed Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 29, 2024) Immunocore Holdings plc (Nasdaq: IMCR), today announced its [...]

Pages